Psychiatry Research Neuroimaging
November 30, 2017
Chiang‐Shan R. Li, Sheng Zhang, Chia-Chun Hung et al.
Chronic ketamine use leads to cognitive and affective deficits including depression. Here, we examined sex differences and neural bases of depression in chronic ketamine users. Compared to non-drug using healthy controls (HC), ketamine-using females but not males showed increased depression score as assessed by the Center of Epidemiological Studies Depression Scale (CES-D). We evaluated resting...
Current Psychiatry Reports
November 15, 2017
Carolina Medeiros da Frota Ribeiro, Patricio Riva-Posse
The purpose of this paper is to provide a review of the use of ketamine as an antidepressant for treatment-resistant depression (TRD) in the geriatric population. Available treatment options for late-life treatment-resistant depression are limited and include electroconvulsive therapy and transcranial magnetic stimulation as well as possible pharmacologic augmentation. Ketamine has been shown...
Trends in Psychiatry and Psychotherapy
November 11, 2017
Lysa Remy, Juliana Nichterwitz Scherer, Luciano Santos Pinto Guimarães et al.
12 citations
Abstract Background This study examined drug use patterns and psychiatric symptoms of anxiety and depression among young Brazilian sexual minority ecstasy and LSD users and compared findings with those reported for their heterosexual peers. Method This cross-sectional study employed targeted sampling and ethnographic mapping approaches via face-to-face interviews conducted at bars and...
Scientific Reports
November 10, 2017
Youge Qu, Chun Yang, Qian Ren et al.
126 citations
Accumulating evidence suggests a key role of the gut-microbiota-brain axis in the antidepressant actions of certain compounds. Ketamine, an N-methyl-D-aspartate receptor (NMDAR) antagonist, showed rapid and sustained antidepressant effects in treatment-resistant depressed patients. In contrast, another NMDAR antagonist, lanicemine, did not exhibit antidepressant effects in such patients....
Journal of Neuroscience
November 8, 2017
Lindsey Friend, Jared Weed, Philip Sandoval et al.
The VTA is necessary for reward behavior with dopamine cells critically involved in reward signaling. Dopamine cells in turn are innervated and regulated by neighboring inhibitory GABA cells. Using whole-cell electrophysiology in juvenile-adolescent GAD67-GFP male mice, we examined excitatory plasticity in fluorescent VTA GABA cells. A novel CB1-dependent LTD was induced in GABA cells that was...
Psychopharmacology
November 8, 2017
R. L. Carhart-Harris, Mark Bolstridge, C. M. J. Day et al.
978 citations
RATIONALE: Recent clinical trials are reporting marked improvements in mental health outcomes with psychedelic drug-assisted psychotherapy. OBJECTIVES: Here, we report on safety and efficacy outcomes for up to 6 months in an open-label trial of psilocybin for treatment-resistant depression. METHODS: Twenty patients (six females) with (mostly) severe, unipolar, treatment-resistant major...
Medical Teacher
November 7, 2017
Zahra Daya, Jasmine Heath Hearn
225 citations
INTRODUCTION: Mindfulness-based interventions (MBIs) have gained popularity in medical education. A systematic review was conducted to determine the effectiveness of MBIs for reducing psychological distress in undergraduate medical students. METHODS: A search protocol was conducted using online databases Embase, PubMed, PsycINFO, and MEDLINE. Articles were required to meet the following...
Mindfulness
November 4, 2017
Amanda J Shallcross, Tanya M Spruill
This study examined the potential buffering role of trait mindfulness in the relationship between perceived discrimination and depressive symptoms in a community-based sample of racial and ethnic minority adults. Analyses conducted on 97 participants indicated that self-reported trait mindfulness moderated the relationship between perceived discrimination and depressive symptoms. Individuals...
Journal watch
November 3, 2017
In 1970, the FDA categorized psilocybin as a Schedule 1 drug, largely because of its recreational uses, which include inducing spirituality and
Journal of Consulting and Clinical Psychology
November 1, 2017
Corey Roos, Sarah Bowen, Katie Witkiewitz
Objective: Few studies have evaluated moderators of mindfulness-based relapse prevention (MBRP) for substance use disorders (SUDs). We tested whether baseline patterns of scores for SUD symptom severity and depression and anxiety symptoms moderated the efficacy of MBRP. Method: We used a latent class moderation approach with data from a randomized trial of MBRP compared to cognitive–behavioral...